# Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

> **NCT00321854** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 535 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** pramipexole

## Key facts

- **NCT ID:** NCT00321854
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-04
- **Final completion:** —
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321854, "Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00321854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*